Register Login

SAB Biotherapeutics (SABSW)

(10% Negative) SAB Biotherapeutics (SABSW) Announces Delay in investors Trials for relation to holding Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 6:49 p.m.

    📋 SAB Biotherapeutics (SABSW) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 16:47:55

    Event Type: Clinical Trial Update

    Event Details:

    SAB Biotherapeutics (SABSW) Announces Clinical Trial Update SAB Biotherapeutics (SABSW) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: investors, given
    • Diseases/Conditions: relation to holding
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: SAB Biotherapeutics, Inc.
      • targeting multiple immune cells involved in destroying pancreatic beta cells, including the modulation of “bad acting” T-lymphocytes Mechanism of action, analogous to rabbit ATG (rATG), directly modulates multiple immune cells involved in destroying pancreatic beta cells SAB-142 provides a better safety profile resulting in no serum sickness and low/no immunogenicity – this offers the potential for life-long disease modification through redosing safely, preserving C-peptide, and delaying the onset or progression of T1D By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells C-peptide is a stable marker of endogenous insulin production Preserving beta cell function and thus insulin production as measured by C-peptide is key to delaying progression of T1D SAB-142 Anti-Thymocyte Globulin (Human) Company Logo © 2026
      • targeting biologics Demonstrated correlation with C-peptide preservation based on precedent rATG studies and natural course of T1D No sustained lymphodepletion leading to immuno-suppression; no neutropenia No serum sickness PK/PD SAB-142’s Phase 1 Data Demonstrated Clinically-validated, Multi-specific MOA with Sustained Immunomodulation Phase 1: HUMAN* Trial Study Design *HUman anti-thymocyte biologic in first-in-MAN clinical study Randomized, double-blind, placebo-controlled, single- and multiple- ascending dose, adaptive design clinical study HV Randomized 1.5 mg/kg n=6 0.5 mg/kg n=12 0.1 mg/kg n=6 0.03 mg/kg n=4 Placebo n=16 T1D Cohort 4.5 mg/kg n=6 2.5 mg/kg n=4 Placebo n=2 Redosing Cohort 1.5 mg/kg n=7 Placebo n=1 2.5 mg/kg n=12 Company Logo © 2026

    🔬 Clinical Development Pipeline (SAB Biotherapeutics):

    Product Type Development Stage Therapeutic Area Source
    Pegfilgrastim (drug) DRUG Phase PHASE2 Epithelial Ovarian Cancer ClinicalTrials.gov
    Biological/Vaccine: NK Cell Therapy Product Derived from Induced Pluripotent Stem Cells (iPSCs) Engineered with Anti-DLL3 CAR Construct, Followed by Differentiation and Expansion BIOLOGICAL Phase PHASE1 SCLC, Extensive Stage ClinicalTrials.gov
    Placebo OTHER Phase PHASE1 Healthy Participants ClinicalTrials.gov
    ALC01 therapy BIOLOGICAL Phase PHASE1 Parkinson Disease ClinicalTrials.gov
    Nitric Oxide modified treatment DRUG Phase PHASE2 Venous Ulcers ClinicalTrials.gov
    EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter DRUG Phase PHASE2 Metastatic Colorectal Cancer ClinicalTrials.gov
    EMB-01 1600 mg administered once weekly throughout the study DRUG Phase PHASE2 Metastatic Colorectal Cancer ClinicalTrials.gov
    LTG-321 DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    LX111 Injection GENETIC Phase EARLY_PHASE1 Diabetic Macular Edema (DME) ClinicalTrials.gov
    LTG-001 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    UTAA07 injection DRUG Phase EARLY_PHASE1 Hematolymphoid Malignancies ClinicalTrials.gov
    CAR-T cell infusion DRUG Phase EARLY_PHASE1 Hematolymphoid Malignancies ClinicalTrials.gov
    LTG-001 Formulation B prototype 2 DRUG Phase PHASE1 Pain Management ClinicalTrials.gov
    LTG-001 Formulation A Prototype 1 DRUG Phase PHASE1 Pain Management ClinicalTrials.gov
    LTG-001 SDD DRUG Phase PHASE1 Pain Management ClinicalTrials.gov
    TORL-2-307-ADC DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Suzetrigine DRUG Phase PHASE2 Acute Pain, Postoperative ClinicalTrials.gov
    LTG-001 Low Dose DRUG Phase PHASE2 Acute Pain, Postoperative ClinicalTrials.gov
    LTG-001 Mid Dose DRUG Phase PHASE2 Acute Pain, Postoperative ClinicalTrials.gov
    LTG-001 High Dose DRUG Phase PHASE2 Acute Pain, Postoperative ClinicalTrials.gov
    Placebo Comparator DRUG Phase PHASE2 Acute Pain ClinicalTrials.gov
    Active Comparator: HB/APAP DRUG Phase PHASE2 Acute Pain ClinicalTrials.gov
    Experimental: LTG-001 Low Dose DRUG Phase PHASE2 Acute Pain ClinicalTrials.gov
    Experimental: LTG-001 High Dose DRUG Phase PHASE2 Acute Pain ClinicalTrials.gov
    Aflibercept BIOLOGICAL Phase PHASE3 Neovascular Age-Related Macular Degeneration (nAMD) ClinicalTrials.gov
    LX102 GENETIC Phase PHASE3 Neovascular Age-Related Macular Degeneration (nAMD) ClinicalTrials.gov
    LV009 Injection Infusion BIOLOGICAL Phase EARLY_PHASE1 Non-Hodgkin Lymphoma (NHL) ClinicalTrials.gov
    Placebo injection for IV infusion DRUG Phase EARLY_PHASE1 Healthy ClinicalTrials.gov
    ABX1100 injection for IV infusion DRUG Phase EARLY_PHASE1 Healthy ClinicalTrials.gov
    TORL-1-23 DRUG Phase PHASE2 Epithelial Ovarian Cancer ClinicalTrials.gov
    KEYTRUDA® BIOLOGICAL Phase PHASE1 Lung Cancer ClinicalTrials.gov
    TILT-123 BIOLOGICAL Phase PHASE1 Lung Cancer ClinicalTrials.gov
    LV009 Injection BIOLOGICAL Phase PHASE1 Non-Hodgkin Lymphoma ClinicalTrials.gov
    Cobicistat 150 MG [Tybost] DRUG Phase EARLY_PHASE1 BRAF V600E Mutation ClinicalTrials.gov
    Plixorafenib DRUG Phase EARLY_PHASE1 BRAF V600E Mutation ClinicalTrials.gov
    Low Dose SAB-142 DRUG Phase PHASE2 Type 1 Diabetes ClinicalTrials.gov
    High Dose SAB-142 DRUG Phase PHASE2 Type 1 Diabetes ClinicalTrials.gov
    GB221 BIOLOGICAL Phase PHASE1 Spinal Muscular Atrophy Type I ClinicalTrials.gov
    T cell injection targeting CD7 chimeric antigen receptor BIOLOGICAL Phase PHASE2 CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma ClinicalTrials.gov
    PBKR03 BIOLOGICAL Phase PHASE1 Leukodystrophy, Globoid Cell ClinicalTrials.gov
    Senza5 CART5 DRUG Phase PHASE1 T Cell Non-Hodgkin Lymphoma ClinicalTrials.gov
    pegylated liposomal doxorubicin DRUG Phase PHASE1 Platinum-refractory Ovarian Carcinoma ClinicalTrials.gov
    pembrolizumab BIOLOGICAL Phase PHASE1 Platinum-refractory Ovarian Carcinoma ClinicalTrials.gov
    TORL-3-600 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    KBA1412 DRUG Phase PHASE1 Advanced Solid Tumor Malignancy ClinicalTrials.gov
    Dose Level 4, VNX-202 GENETIC Phase PHASE1 HER2 Expressing Solid Tumors ClinicalTrials.gov
    Dose Level 3, VNX-202 GENETIC Phase PHASE1 HER2 Expressing Solid Tumors ClinicalTrials.gov
    Dose Level 2, VNX-202 GENETIC Phase PHASE1 HER2 Expressing Solid Tumors ClinicalTrials.gov
    Dose Level 1, VNX-202 GENETIC Phase PHASE1 HER2 Expressing Solid Tumors ClinicalTrials.gov
    Dose Level 4, VNX-101 GENETIC Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ClinicalTrials.gov
    Dose Level 3, VNX-101 GENETIC Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ClinicalTrials.gov
    Dose Level 2, VNX-101 GENETIC Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ClinicalTrials.gov
    Dose Level 1, VNX-101 GENETIC Phase PHASE1 B-cell Acute Lymphoblastic Leukemia ClinicalTrials.gov
    SUPLEXA BIOLOGICAL Phase PHASE1 Oncology ClinicalTrials.gov
    OBT076, a CD205-directed antibody-drug conjugate DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    EBI-005-2 DRUG Phase PHASE1 Dry Eye Syndrome ClinicalTrials.gov
    Terbinafine HCl DRUG Phase PHASE2 Onychomycosis ClinicalTrials.gov
    Nitric Oxide DRUG Phase PHASE1 Leg Ulcer ClinicalTrials.gov
    Purified Water OTHER Phase PHASE2 Onychomycosis ClinicalTrials.gov
    Terbinafine Hydrochloride DRUG Phase PHASE2 Onychomycosis ClinicalTrials.gov
    GBT009 BIOLOGICAL Phase PHASE2 Scar Formation ClinicalTrials.gov
    Nitric Oxide 200ppm Group B DRUG Phase PHASE2 Venous Ulcers ClinicalTrials.gov
    Nitric Oxide - same dose 6 wks DRUG Phase PHASE2 Venous Ulcers ClinicalTrials.gov
    1% gaseous Nitric Oxide blended in Oxygen DRUG Phase PHASE2 Tinea Pedis ClinicalTrials.gov
    EBI-005-1 Placebo DRUG Phase PHASE1 Dry Eye ClinicalTrials.gov
    EBI-005-1 DRUG Phase PHASE1 Dry Eye ClinicalTrials.gov
    Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594) DRUG Phase PHASE2 Colorectal Carcinoma ClinicalTrials.gov
    JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF) GENETIC Phase PHASE1 Neoplasms, Liver ClinicalTrials.gov
    EBI-005 DRUG Phase PHASE3 Allergic Conjunctivitis (AC) ClinicalTrials.gov
    IGN523 DRUG Phase PHASE1 Acute Myelogenous Leukemia ClinicalTrials.gov
    JX-594 BIOLOGICAL Phase PHASE1 Melanoma ClinicalTrials.gov
    EBI-031 DRUG Phase PHASE1 Diabetic Macular Edema ClinicalTrials.gov
    Best Supportive Care OTHER Phase PHASE2 Hepatocellular Carcinoma ClinicalTrials.gov
    JX-594 recombinant vaccina GM-CSF BIOLOGICAL Phase PHASE2 Hepatocellular Carcinoma ClinicalTrials.gov
    Active Comparator EBI-005 5 mg/mL DRUG Phase PHASE2 Allergic Conjunctivitis ClinicalTrials.gov
    JX-594 followed by sorafenib DRUG Phase PHASE2 Carcinoma, Hepatocellular ClinicalTrials.gov
    PCAR-019 (anti-CD19 CAR-T cells) BIOLOGICAL Phase PHASE1 Acute Lymphocytic Leukemia ClinicalTrials.gov
    Active Comparator EBI-005 DRUG Phase PHASE3 Dry Eye Disease (DED) ClinicalTrials.gov
    0.3X ACCS DRUG Phase PHASE1 Gingivitis ClinicalTrials.gov
    Normal saline DRUG Phase PHASE1 Gingivitis ClinicalTrials.gov
    1X ACCS (Amnion-derived Cellular Cytokine Solution) DRUG Phase PHASE1 Gingivitis ClinicalTrials.gov
    PINTA 745 DRUG Phase PHASE1 End Stage Renal Disease ClinicalTrials.gov
    anti-CD7 CAR-pNK cells BIOLOGICAL Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    anti-CD33 CAR-NK cells BIOLOGICAL Phase PHASE1 Acute Myelogenous Leukemia ClinicalTrials.gov
    Liposomal doxorubicin DRUG Phase PHASE1 Ovarian Cancer ClinicalTrials.gov
    STM 434 DRUG Phase PHASE1 Ovarian Cancer ClinicalTrials.gov
    GRN-1201 BIOLOGICAL Phase PHASE1 Melanoma ClinicalTrials.gov
    anti-CD19 CAR-NK cells BIOLOGICAL Phase PHASE1 Acute Lymphocytic Leukemia ClinicalTrials.gov
    Normal (9%) Saline OTHER Phase PHASE1 Middle East Respiratory Syndrome Coronavirus ClinicalTrials.gov
    SAB-301 BIOLOGICAL Phase PHASE1 Middle East Respiratory Syndrome Coronavirus ClinicalTrials.gov
    anti-MUC1 CAR-T cells BIOLOGICAL Phase PHASE1 Malignant Glioma of Brain ClinicalTrials.gov
    AB-16B5 DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    anti-MUC1 CAR T Cells BIOLOGICAL Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    anti-MUC1 CAR-pNK cells BIOLOGICAL Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    ST266 BIOLOGICAL Phase PHASE1 Burns ClinicalTrials.gov
    FGF-1 DRUG Phase PHASE1 Chronic Wounds ClinicalTrials.gov
    Esomeprazole DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    Itraconazole DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    Midazolam DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    BBT-877 DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    CD19-CART DRUG Phase EARLY_PHASE1 B Acute Lymphoblastic Leukemia ClinicalTrials.gov
    CD19 CAR-T cells infusion BIOLOGICAL Approved Non Hodgkin Lymphoma ClinicalTrials.gov
    BBT-877, Multiple doses DRUG Phase PHASE1 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov
    Placebo group DRUG Phase PHASE1 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov
    BBT-877, Single dose DRUG Phase PHASE1 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov
    Briagen DEVICE Preclinical Mohs Surgery ClinicalTrials.gov
    CD7 CAR-T cells infusion DRUG Phase PHASE1 T-lymphoblastic Lymphoma ClinicalTrials.gov
    ST266 delayed BIOLOGICAL Phase PHASE2 Skin Burns ClinicalTrials.gov
    ST266 immediate BIOLOGICAL Phase PHASE2 Skin Burns ClinicalTrials.gov
    Refresh Lubricant Eye Drops DRUG Phase PHASE1 Dry Eye Syndrome ClinicalTrials.gov
    BCMA-CART cells BIOLOGICAL Phase EARLY_PHASE1 Multiple Myeloma ClinicalTrials.gov
    Autologous chimeric antigen receptor T cell transfusing agent targeting CD22 DRUG Phase PHASE1 Diffuse Large B Cell Lymphoma ClinicalTrials.gov
    Placebo single dose DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    BBT-877 single dose DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    Saline DRUG Phase PHASE2 Third Degree Burns ClinicalTrials.gov
    CD19/CD20 CAR-T cell infusion DRUG Phase EARLY_PHASE1 CAR ClinicalTrials.gov
    CAR-T DRUG Phase EARLY_PHASE1 CAR-T ClinicalTrials.gov
    PLX8394 DRUG Phase PHASE1 Melanoma ClinicalTrials.gov
    EIDD-2801 DRUG Phase PHASE1 Coronavirus ClinicalTrials.gov
    IRL201104 DRUG Phase PHASE1 Healthy Volunteer ClinicalTrials.gov
    Irinotecan DRUG Phase PHASE1 Colorectal Carcinoma ClinicalTrials.gov
    Chimeric antigen receptor modified γδ T cells DRUG Phase EARLY_PHASE1 CAR ClinicalTrials.gov
    Targeting CD276 autologous chimeric antigen receptor T cells DRUG Approved CAR ClinicalTrials.gov
    Targeting CD276 CAR T cells DRUG Phase EARLY_PHASE1 Osteosarcoma ClinicalTrials.gov
    Humanized CD7 CAR-T cells BIOLOGICAL Phase PHASE1 T Lymphoblastic Leukemia/Lymphoma ClinicalTrials.gov
    γδT Cell infusion agent DRUG Phase EARLY_PHASE1 Leukemia, B-cell ClinicalTrials.gov
    Chimeric antigen receptor T cells (car-t) OTHER Approved CAR ClinicalTrials.gov
    PSB205 BIOLOGICAL Phase PHASE1 Neoplasm Malignant ClinicalTrials.gov
    T cell infusion agent targeting BCMA chimeric antigen receptor DRUG Phase EARLY_PHASE1 Multiple Myeloma ClinicalTrials.gov
    Saline (0.9% NaCl) DRUG Phase PHASE2 Periodontal Disease ClinicalTrials.gov
    Fludarabine + Cyclophosphamide + TAA05 Cell Injection DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    PSB202 DRUG Phase PHASE1 Follicular Lymphoma ClinicalTrials.gov
    Carboplatin DRUG Phase PHASE3 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    Paclitaxel DRUG Phase PHASE3 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    Avastin (bevacizumab) DRUG Phase PHASE3 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    FKB238 (bevacizumab) DRUG Phase PHASE3 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    NBL-012 Injection DRUG Phase PHASE1 Healthy Subjects ClinicalTrials.gov
    Placebo (PBO) DRUG Phase PHASE2 SARS-CoV-2 Infection, COVID-19 ClinicalTrials.gov
    Molnupiravir 800 mg DRUG Phase PHASE2 SARS-CoV-2 Infection, COVID-19 ClinicalTrials.gov
    Molnupiravir 400 mg DRUG Phase PHASE2 SARS-CoV-2 Infection, COVID-19 ClinicalTrials.gov
    Molnupiravir 200 mg DRUG Phase PHASE2 SARS-CoV-2 Infection, COVID-19 ClinicalTrials.gov
    SAB-185 BIOLOGICAL Phase PHASE1 COVID-19 ClinicalTrials.gov
    TAA06 injection BIOLOGICAL Phase PHASE1 Malignant Melanoma, Lung Cancer, or Colorectal Cancer ClinicalTrials.gov
    T cell injection targeting FLT3 chimeric antigen receptor BIOLOGICAL Phase EARLY_PHASE1 FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia ClinicalTrials.gov
    NBL-015 DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    TAA05 cell injection DRUG Approved CAR ClinicalTrials.gov
    T cell injection targeting B7-H3 chimeric antigen receptor BIOLOGICAL Phase PHASE1 B7-H3-positive Relapsed/ Refractory Neuroblastoma ClinicalTrials.gov
    Open-label ST266 BIOLOGICAL Phase PHASE2 Persistent Corneal Epithelial Defect ClinicalTrials.gov
    0.67% Sodium Chloride Ophthalmic Solution OTHER Phase PHASE2 Persistent Corneal Epithelial Defect ClinicalTrials.gov
    NBP Softgel Capsules DRUG Phase PHASE2 Breast Cancer ClinicalTrials.gov
    JCXH-211 Injection DRUG Phase PHASE1 Cutaneous Tumor ClinicalTrials.gov
    AG-80308 DRUG Phase PHASE1 Dry Eye Disease ClinicalTrials.gov
    GRN-1201 + Pembrolizumab BIOLOGICAL Phase PHASE2 Metastatic NSCLC ClinicalTrials.gov
    B7-H3 target, CAR gene modified gdT cell injection BIOLOGICAL Phase PHASE1 Relapsed/Refractory Acute Myeloid Leukemia ClinicalTrials.gov
    Stemchymal® BIOLOGICAL Phase PHASE1 Stem Cells ClinicalTrials.gov
    Excipients PROCEDURE Phase PHASE2 Cerebellar Ataxia ClinicalTrials.gov
    gdT cell injection targeting B7-H3 chimeric antigen receptor BIOLOGICAL Phase EARLY_PHASE1 Relapsed/Refractory Acute Myeloid Leukemia ClinicalTrials.gov
    Osimertinib DRUG Phase PHASE1 Metastatic Lung Non-Small Cell Carcinoma ClinicalTrials.gov
    EMB-01 DRUG Phase PHASE1 Metastatic Lung Non-Small Cell Carcinoma ClinicalTrials.gov
    LX103 Injection GENETIC Approved X-linked Retinoschisis ClinicalTrials.gov
    JCXH-211 DRUG Phase PHASE1 Cutaneous Tumor ClinicalTrials.gov
    CPO102 DRUG Phase PHASE1 Pancreatic Cancer ClinicalTrials.gov
    LX102-C01 Injection GENETIC Approved Neovascular Age-related Macular Degeneration ClinicalTrials.gov
    Adipose-Derived Mesenchymal Stem Cells DRUG Phase PHASE1 Osteoarthritis Knee ClinicalTrials.gov
    Matching Placebo DRUG Phase PHASE1 Heart Failure With Preserved Ejection Fraction ClinicalTrials.gov
    JK07 DRUG Phase PHASE1 Heart Failure With Preserved Ejection Fraction ClinicalTrials.gov
    BBT-401-1S or Placebo DRUG Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    NBL-028 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    EMB-02 BIOLOGICAL Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    EMB-09 BIOLOGICAL Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    UTAA17 Injection BIOLOGICAL Approved Relapsed/Refractory Multiple Myeloma ClinicalTrials.gov
    T cell injection targeting CD19 chimeric antigen receptor BIOLOGICAL Phase EARLY_PHASE1 Systemic Lupus Erythematosus ClinicalTrials.gov
    NBL-020 for Injection DRUG Phase PHASE1 Advanced Malignant Tumors ClinicalTrials.gov
    TAVO103A DRUG Phase PHASE1 Healthy Subjects ClinicalTrials.gov
    EBT-101 BIOLOGICAL Phase PHASE1 HIV-1-infection ClinicalTrials.gov
    ALK202 DRUG Phase PHASE1 Advanced Cancer ClinicalTrials.gov
    SAB-176 BIOLOGICAL Phase PHASE2 Influenza A H1N1 ClinicalTrials.gov
    Cobicistat DRUG Phase PHASE2 Cancer Harboring BRAF Alterations ClinicalTrials.gov
    TAVO412 DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    LX101 GENETIC Phase PHASE3 Inherited Retinal Dystrophy Associated With RPE65 Mutations ClinicalTrials.gov
    LX107 Injection GENETIC Phase EARLY_PHASE1 Retinal Dystrophy ClinicalTrials.gov
    EMB-06 BIOLOGICAL Phase PHASE1 Relapsed or Refractory Multiple Myeloma ClinicalTrials.gov
    TORL-4-500 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Sotevtamab BIOLOGICAL Phase PHASE2 Metastatic Colorectal Cancer ClinicalTrials.gov
    ALETA-001 DRUG Phase PHASE1 Lymphoma, Non-Hodgkin ClinicalTrials.gov
    UTAA91 injection BIOLOGICAL Phase EARLY_PHASE1 Systemic Lupus Erythematosus ClinicalTrials.gov
    PBGM01 BIOLOGICAL Phase PHASE1 GM1 Gangliosidosis ClinicalTrials.gov
    ALK201 DRUG Phase PHASE1 Advanced Cancer ClinicalTrials.gov
    LTG-305 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    EMB07 DRUG Phase PHASE1 Advanced/Metastatic Solid Tumors ClinicalTrials.gov
    LX102 subretinal injection GENETIC Phase PHASE1 Neovascular Age-Related Macular Degeneration ClinicalTrials.gov
    pregabalin 300 mg DRUG Phase EARLY_PHASE1 Pain Detection ClinicalTrials.gov
    Fludarabine DRUG Phase PHASE1 Metastatic Melanoma ClinicalTrials.gov
    Cyclophosphamide DRUG Phase PHASE1 Metastatic Melanoma ClinicalTrials.gov
    TIL BIOLOGICAL Phase PHASE1 Metastatic Melanoma ClinicalTrials.gov
    UTAA09 cells for infusion BIOLOGICAL Phase EARLY_PHASE1 CD19-positive Relapsed or Refractory B-cell Malignancies ClinicalTrials.gov
    TORL-2-307-MAB DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Single Ascending Dose of Placebo DRUG Phase PHASE1 PHA1A ClinicalTrials.gov
    Single Ascending Dose of SAB-176 DRUG Phase PHASE1 PHA1A ClinicalTrials.gov
    FORE8394 DRUG Phase PHASE1 Advanced Unresectable Solid Tumors ClinicalTrials.gov
    Docetaxel DRUG Phase PHASE2 NSCLC Stage IV ClinicalTrials.gov
    Part B - mutiple rising dose 2 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Part B - mutiple rising dose 1 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Part A - single rising dose 6 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Part A - single rising dose 5 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Part A - single rising dose 4 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Part A - single rising dose 3 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Part A - single rising dose 2 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Part A - single rising dose 1 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Ansuvimab DRUG Preclinical Ebola Virus Disease ClinicalTrials.gov
    Aflibercept intravitreal injection BIOLOGICAL Phase PHASE2 Neovascular Age-Related Macular Degeneration ClinicalTrials.gov
    Other: Placebo OTHER Phase PHASE1 Healthy Subjects ClinicalTrials.gov
    Experimental: TAVO101 DRUG Phase PHASE1 Healthy Subjects ClinicalTrials.gov
    NEUK203-215 Injection GENETIC Phase EARLY_PHASE1 Autoimmune ClinicalTrials.gov
    Cyclophosphamide (C) DRUG Phase EARLY_PHASE1 Autoimmune ClinicalTrials.gov
    Avelumab DRUG Phase PHASE1 Melanoma ClinicalTrials.gov
    suzetrigine 100mg DRUG Phase EARLY_PHASE1 Pain Detection ClinicalTrials.gov
    TAVO101 DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    ICA07 therapy BIOLOGICAL Phase PHASE1 Parkinson Disease ClinicalTrials.gov
    Long Term Safety Monitoring Procedures OTHER Preclinical Rheumatoid Arthritis (RA) ClinicalTrials.gov
    SPH3127 DRUG Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: SAB Biotherapeutics
    • Ticker Symbol: SABSW

Search

News categories